MA-EDB
9.12.2021 15:02:04 CET | Business Wire | Press release
EDB , an open source innovator and the leading contributor to PostgreSQL®, announced today the worldwide immediate availability of EDB 14, its premiere PostgreSQL platform. EDB® 14 adds critical enterprise capabilities, including extreme high availability and multi-master replication, which are necessary for running today’s mission-critical applications, whether high-speed transactional systems in financial services or geo-distributed analytical systems in retail. Further improvements to EDB’s powerful Oracle database compatibility technology enable even smoother migration, which is essential for the growing number of organizations moving to the cloud.
“Postgres is the fastest growing database platform worldwide with rapid adoption by developers and enterprises," Marc Linster, CTO, EDB. "With EDB 14, we've pushed Postgres even further to support our customers’ most demanding workloads and help them migrate faster at a lower total cost of ownership. This release offers even more incentive for businesses to move away from traditional databases and get onto Postgres now, or get more from it if they’re already there."
EDB 14 highlights
With the largest team of PostgreSQL engineers of any other software vendor, EDB continues to strengthen PostgreSQL to help enterprises do more and go faster. Highlights include:
- Extreme high availability : Postgres-BDR®, a component of the EDB 14 release, allows customers to run PostgreSQL with 99.999% availability through its innovative multi-master replication capability, a feature no other PostgreSQL database offers. Multi-master replication allows customers to operate their PostgreSQL databases in “Always On” architectures with zero downtime updates and upgrades, which is critical for keeping their databases running optimally and securely.
- Enhanced Oracle database compatibility : EDB Postgres Advanced ServerTM adds features that further improve compatibility with Oracle database technology. This capability is vital for customers looking to move applications or data from Oracle database to PostgreSQL and benefit from its superior usability and reduced operational and licensing costs.
- Improved DevOps for PostgreSQL : EDB’s Cloud Native PostgreSQL, another component of EDB 14, helps Kubernetes users take full advantage of PostgreSQL as their database of choice. This latest version of Cloud Native PostgreSQL provides connection pooling to enable workloads with many concurrent connections to run in Kubernetes, supporting applications with even higher user demands than before.
- Deployment flexibility : PostgreSQL customers can deploy EDB 14 in any manner, including using EDB’s BigAnimalTM , the first fully managed PostgreSQL database in the cloud with compatibility for Oracle database technology, or self-manage their database on premises.
- Choice of PostgreSQL distributions : The EDB 14 platform has been tested with PostgreSQL 14 and EDB Postgres Advanced Server 14, enabling customers to choose between PostgreSQL distributions and tools, including open source, EDB, or a combination.
To learn more about EDB 14, visit the EDB blog . For details about BigAnimal and to sign up for a free trial, visit www.BigAnimal.com .
About EDB
PostgreSQL is increasingly the database of choice for organizations looking to boost innovation and accelerate business. EDB’s enterprise-class software extends PostgreSQL, helping our customers get the most out of it both on premises and in the cloud. And our 24x7 global support, professional services, and training help our customers control risk, manage costs, and scale efficiently. With 16 offices worldwide, EDB serves over 5,000 customers, including leading financial services, government, media and communications, and information technology organizations. To learn about PostgreSQL for people, teams, and enterprises, visit EDBpostgres.com .
EnterpriseDB, EDB and Postgres Enterprise Manager are registered trademarks of EnterpriseDB Corporation. EDB Postgres is a trademark of EnterpriseDB Corporation.
Postgres, PostgreSQL, and the Slonik Logo are trademarks or registered trademarks of the PostgreSQL Community Association of Canada, and used with their permission.
Oracle, Java, and MySQL are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005194/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom